key: cord-0989820-1vm30kn1
authors: Delaleu, Jérémie; Deniau, Benjamin; Battistella, Maxime; de Masson, Adèle; Bensaid, Benoit; Jachiet, Marie; Lazaridou, Ingrid; Bagot, Martine; Bouaziz, Jean-David
title: Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19
date: 2020-06-07
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.05.046
sha: e08b9014a4cf224617721d645875d2f28d6aee56
doc_id: 989820
cord_uid: 1vm30kn1

nan

Hydroxychloroquine is now commonly used off-label for treatment of COVID-19 in 40 combinations with drugs, at doses and in populations where it is not typically used. We 41 present a case that highlights that even in short course therapy acute generalized 42 exanthematous pustulosis should be recognized as a potential adverse effect of 43

Acute generalized exanthematous pustulosis (AGEP) is a rare drug reaction characterized by 45 acute, extensive formation of numerous non-follicular sterile pustules on a background of 46 edematous erythema. 1 Hydroxychloroquine (HCQ), is widely used to treat rheumatic and 47 dermatologic diseases, and is well known to cause AGEP. 1 At the end of 2019, a novel 48 coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, city of 49

China. It rapidly spread in China and outside, and on March 12 th , 2020, the WHO declared a 50 pandemic. HCQ has been reported to inhibit SARS-CoV-2 in vitro but clinical data evaluating 51 HCQ are limited, and its efficacy against SARS-CoV-2 is unknown. Nevertheless, given the 52 lack of clearly effective interventions, HCQ is being used off-label in combination with drugs, 53 at doses and in populations where it would not be traditionally used. Therefore, vigilance 54 needs to be applied especially if this drug is not being used in clinical trials settings where 55 adverse-event information and monitoring are more meticulous. Herein we report a case of 56 AGEP induced by HCQ prescribed for COVID-19. We also reviewed literature about HCQ 57 induced AGEP and efficacy of HCQ in COVID-19. including HCQ, are often associated with latencies around 10-12 days or longer (16.2 days for 100 HCQ in our review) 6 . The latency period of 9 days in our patient was shorter than described. 101

The dysregulation of the Th17 pathway observed in cytokine storm induced by COVID-19 102 may explain a shorter delay of AGEP induced by HCQ. The PubMed database was searched 103 for all peer-reviewed articles published until April 2020 using the following search terms: 104 "hydroxychloroquine" and "acute generalized exanthematous pustulosis" and found 35 cases 105 (Table E- 

Use of HCQ is included in Chinese treatment guidelines and was reportedly associated with 107 reduced disease progression. However, data supporting these claims are controversial. A 108 randomized trial of two different doses of HCQ in 62 COVID-19 patients, reported a better 109 outcome with higher doses 7 . However, the endpoints specified in the protocol differed from 110 those reported and the trial seemed to have stopped prematurely. In an open-label study of 36 111 COVID-19 patients, treatment with azithromycin and HCQ was associated with a more rapid 112 decline in viral RNA 8 . However, there were methodological concerns about the control 113 groups, and another observational study did not confirm these findings 9 . Additionally, in an 114 observational study of nearly 1400 patients with COVID-19 admitted to a hospital in New-115

York, HCQ use was reported in 811 patients and was associated with a higher risk of 116 intubation or death (hazard ratio 2.37) 10 . Despite these facts, some clinicians argued that HCQ 117 is widely used and safe. Furthermore, amid the speculation regarding the beneficial roles of 118 

WBC=8.6x10 9 /L N=7x10 9 /L L=0.4 x10 9 /L Eo= 0.0x10 9 /L Mo=0.5 x10 9 /L PCT=0.91µg/L CRP=200mg/L Il-6=521pg/mL Tg=0.69g/L ALT=43UI/L WBC=13.9 x10 9 /L N=13x10 9 /L L=0.9 x10 9 /L Eo=0. 

Acute generalized 173 exanthematous pustulosis (AGEP)--a clinical reaction pattern

Bacterial and fungal infections in 176 COVID-19 patients: A matter of concern

A case of recalcitrant acute generalized exanthematous 178 pustulosis with Sjogren's syndrome: Successfully treated with low-dose cyclosporine

A case of prolonged generalized exanthematous 181 pustulosis caused by hydroxychloroquine-Literature review

Characterizing the adverse dermatologic 184 effects of hydroxychloroquine: a systematic review

Risk factors for 186 acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-187 control study (EuroSCAR)

Efficacy of hydroxychloroquine in 189 patients with COVID-19: results of a randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-193 label non-randomized clinical trial

No 195 evidence of rapid antiviral clearance or clinical benefit with the combination of 196 hydroxychloroquine and azithromycin in patients with severe COVID-19 infection 197

Observational Study of 200 Hydroxychloroquine in Hospitalized Patients with Covid-19